Jiangsu Hengrui Pharmaceuticals(600276.SH) received acceptance of the application for the marketing license of SHR4640 tablets.
Hengrui Medicine (600276.SH) announced that the company has received a "Notice of Acceptance" issued by the National Medical Products Administration...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has received the "Acceptance Notification" issued by the National Medical Products Administration. The company's application for the market approval of SHR4640 tablets has been accepted by the national drug regulatory authority. The drug is intended for the long-term treatment of primary gout with hyperuricemia.
Related Articles
New stock outlook | Accounts receivable accounts for more than 60% of revenue, how can Youlesai tell a good story of circular packaging?
"Zootopia 2" breaks box office records and tops the animated film box office champion of Walt Disney Company(DIS.US).
The new national medical insurance list will be implemented starting today, benefiting patients with three innovative drugs from SKB BIO-B (06990).
New stock outlook | Accounts receivable accounts for more than 60% of revenue, how can Youlesai tell a good story of circular packaging?
"Zootopia 2" breaks box office records and tops the animated film box office champion of Walt Disney Company(DIS.US).
The new national medical insurance list will be implemented starting today, benefiting patients with three innovative drugs from SKB BIO-B (06990).
